DATE OF RELEASE/EXPIRATIONThe enduring material will be available from September 10, 2021 to September 10, 2022
Jointly provided by Consortium of Multiple Sclerosis Centers (CMSC) and PlatformQ Health Education, LLC (PQHE).
Physicians – 0.5 AMA PRA Category 1 Credit(s)™
Nurses – 0.5 contact hours of nursing continuing professional development (NCPD)
Pharmacists – 0.5 contact hours of continuing pharmacy education credit
PAs – 0.5 AAPA Category 1 CME credit
All other healthcare professionals completing this course will be issued a statement of participation.
This activity has been designed to meet the educational needs of physicians, pharmacists, nursing professionals, PAs, and other members of the healthcare team involved in the management of patients with MS.
Upon completing this activity, participants should be better able to:
- Summarize current and emerging biomarkers in MS, their association with disease development and progression, and their role in making treatment decisions
- Apply current evidence about long-term safety and efficacy outcomes of treatment with high-efficacy DMTs in patients with relapsing and progressive forms of MS
Robert K. Shin, MD, FANA, FAAN
Professor, Department of Neurology
MedStar Georgetown University Hospital
Director, Georgetown Multiple Sclerosis and Neuroimmunology Center
Georgetown University Medical Center
Lilyana Amezcua, MD, MS, FAAN
Associate Professor of Neurology
Multiple Sclerosis Fellowship Program Director
Multiple Sclerosis Comprehensive Care and Research Group
USC, Keck School of Medicine
This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.